These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16711515)

  • 81. In situ hybridization histochemistry of mRNAs for hormones and chromogranins in normal pituitary tissue and pituitary adenoma.
    Kilár F; Muhr C; Funa K
    Acta Endocrinol (Copenh); 1991 Dec; 125(6):628-36. PubMed ID: 1789058
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Serum chromogranin A and its relationship to endogenous markers of glomerular filtration rate.
    Mojiminiyi OA; George S
    Ann Clin Biochem; 1999 Mar; 36 ( Pt 2)():247-9. PubMed ID: 10370749
    [No Abstract]   [Full Text] [Related]  

  • 83. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
    Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
    J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
    [TBL] [Abstract][Full Text] [Related]  

  • 84. How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia?
    O'Connor DT; Deftos LJ
    Ann N Y Acad Sci; 1987; 493():379-86. PubMed ID: 3473967
    [No Abstract]   [Full Text] [Related]  

  • 85. Residual androgen depending in hormone-resistant prostate cancer.
    Fosså SD
    Acta Oncol; 1997; 36(1):81-2. PubMed ID: 9090973
    [No Abstract]   [Full Text] [Related]  

  • 86. [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate].
    Baranowska B; Jeske W; Szymanowski J; Piechna K
    J Urol (Paris); 1983; 89(8):601-5. PubMed ID: 6203986
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Granins and prostate cancer.
    Deftos LJ; Abrahamsson PA
    Urology; 1998 May; 51(5A Suppl):141-5. PubMed ID: 9610570
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
    Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Vigan P; Strada G
    Int J Biol Markers; 2005; 20(2):123-125. PubMed ID: 28207138
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
    Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
    Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
    Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
    Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Melatonin and steroid-dependent carcinomas.
    Oosthuizen JM; Bornman MS; Barnard HC; Schulenburg GW; Boomker D; Reif S
    Andrologia; 1989; 21(5):429-31. PubMed ID: 2817446
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
    J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Chromogranin A in uremia: progressive retention of immunoreactive fragments.
    Hsiao RJ; Mezger MS; O'Connor DT
    Kidney Int; 1990 Mar; 37(3):955-64. PubMed ID: 2313983
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [The prognostic significance of prolactin in prostate cancer].
    Røhl HF; Andersen OP
    Ugeskr Laeger; 1987 Dec; 149(50):3402-3. PubMed ID: 3433541
    [No Abstract]   [Full Text] [Related]  

  • 95. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis.
    Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Chang LS
    BJU Int; 2002 May; 89(7):710-3. PubMed ID: 11966629
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.
    Harper ME; Peeling WB; Cowley T; Brownsey BG; Phillips ME; Groom G; Fahmy DR; Griffiths K
    Acta Endocrinol (Copenh); 1976 Feb; 81(2):409-26. PubMed ID: 946155
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Serum chromogranin A in the differential diagnosis of Cushing's syndrome.
    Nobels FR; de Herder WW; Kwekkeboom DJ; Coopmans W; Mulder A; Bouillon R; Lamberts SW
    Eur J Endocrinol; 1994 Dec; 131(6):589-93. PubMed ID: 7528607
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Chromogranin A blood concentrations in relation to those of prolactin in hormone-refractory metastatic prostate cancer: possible existence of two independent mechanisms responsible for endocrine resistance.
    Lissoni P; Viganò P; Podraska A; Brivio R; Colciago M; Casu M; Manganini V; Giuberti C; Strada G; Gardani G
    Int J Biol Markers; 2006; 21(1):58-9. PubMed ID: 16711515
    [No Abstract]   [Full Text] [Related]  

  • 100. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer.
    Lissoni P; Bignami A; Frontini L; Manganini V; Dapretto E; Gardani GS; Viganò P; Strada G
    Int J Biol Markers; 2005; 20(2):123-5. PubMed ID: 16011043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.